Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Cash & Equivalents: 2020-2025

Historic Cash & Equivalents for Caribou Biosciences (CRBU) over the last 6 years, with Sep 2025 value amounting to $11.1 million.

  • Caribou Biosciences' Cash & Equivalents fell 65.14% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year decrease of 65.14%. This contributed to the annual value of $16.3 million for FY2024, which is 68.15% down from last year.
  • Latest data reveals that Caribou Biosciences reported Cash & Equivalents of $11.1 million as of Q3 2025, which was down 55.78% from $25.2 million recorded in Q2 2025.
  • In the past 5 years, Caribou Biosciences' Cash & Equivalents registered a high of $435.3 million during Q3 2021, and its lowest value of $11.1 million during Q3 2025.
  • In the last 3 years, Caribou Biosciences' Cash & Equivalents had a median value of $37.9 million in 2024 and averaged $43.2 million.
  • Per our database at Business Quant, Caribou Biosciences' Cash & Equivalents surged by 1,673.37% in 2021 and then crashed by 81.14% in 2022.
  • Quarterly analysis of 5 years shows Caribou Biosciences' Cash & Equivalents stood at $240.4 million in 2021, then tumbled by 75.73% to $58.3 million in 2022, then dropped by 12.30% to $51.2 million in 2023, then tumbled by 68.15% to $16.3 million in 2024, then tumbled by 65.14% to $11.1 million in 2025.
  • Its Cash & Equivalents stands at $11.1 million for Q3 2025, versus $25.2 million for Q2 2025 and $29.4 million for Q1 2025.